Reaping the rewards of mechanistic discovery in glomerular disease

被引：0

作者：

Arpita Joshi

Laura H. Mariani

机构：

[1] University of Michigan,Division of Nephrology

来源：

Nature Reviews Nephrology | 2024年 / 20卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Several successfully completed clinical trials of novel therapies in glomerular disease were reported in 2023. Building on important mechanistic discoveries about disease onset and progression over the past several years, these therapies raise hope that multiple options will be available to reduce the risk of kidney failure in glomerular disease.

引用

页码：77 / 78

页数：1

共 12 条

[1] Gleeson PJ(2023)IgA nephropathy in adults – treatment standard Nephrol. Dial. Transplant. 38 2464-2473
[2] O’Shaughnessy MM(2021)A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy Kidney Int. 100 215-224
[3] Barratt J(2023)Long-term outcomes in IGA nephropathy Clin. J. Am. Soc. Nephrol. 18 727-738
[4] Wheeler DC(2022)Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IGA nephropathy J. Am. Med. Assoc. 327 1888-1898
[5] Pitcher D(2023)Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy Kidney Int. 103 391-402
[6] Lv J(2023)Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial Lancet 402 859-870
[7] Barratt J(2023)Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial Lancet 402 2077-2090
[8] Lafayette R(2019)Proteinuria reduction as a surrogate end point in trials of IGA nephropathy Clin. J. Am. Soc. Nephrol. 14 469-481
[9] Rovin BH(2023)Inaxaplin for proteinuric kidney disease in persons with two N. Engl. J. Med. 388 969-979
[10] Thompson A(2023) variants Kidney Int. 104 254-264

← 1 2 →